

ASX Announcement (ASX:HLS)

ASX Limited
Market Announcements
Office Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

11 May 2023

APPOINTMENT OF GROUP EXECUTIVE, HEALIUS PATHOLOGY

Healius Limited (Healius) (ASX: HLS) today announces the appointment of Dr Jan Van Rooyen to the role of Group Executive, Healius Pathology effective from 1 June 2023. Dr Van Rooyen replaces Mr John McKechnie who will step down from a full-time role on 30 June 2023 and remain in an advisory capacity as he transitions to retirement. Dr Van Rooyen's appointment continues to refresh and strengthen the Healius Executive Leadership Team under the Managing Director and Chief Executive Officer, Ms Maxine Jaquet.

Dr Van Rooyen is both a Pathologist and a business leader and was the Chief Executive Officer of AMPATH in South Africa for nearly 20 years. Under Dr Van Rooyen's leadership, AMPATH was transformed clinically and operationally from a collection of independent practices to a market-leading nationally consolidated business with a common support and IT infrastructure.

Ms Jaquet said: "After an extensive domestic and international search, I am delighted to appoint Jan to the role of Group Executive, Pathology. He brings a rare combination of clinical expertise in pathology and commercial leadership. At AMPATH Jan created a culture driven by clinical excellence and more than doubled the size of the business with mid-teens annual earnings growth over his tenure."

Dr Van Rooyen said: "I am very pleased to be joining Healius and to lead its Pathology business at such an interesting time of rapid developments in diagnosis and in personalisation of medicine. Pathology is a global industry and there are many parallels between the South African and Australian pathology markets. I look forward to working with Maxine and the Healius team and applying my knowledge to grow this business."

Dr Van Rooyen will be supported by Mr Ian McPhan, the Chief Operating Officer, and by the highly-qualified clinical and operational teams at Healius Pathology.

Together with Dr Phil Lucas who is the Group Executive, Lumus Imaging and was one of the founders of PRP Diagnostic Imaging, Healius has good operational bench strength to deliver on the next generation diagnostics strategy and growth agenda.

ENDS

The release of this announcement has been authorised by the Chair.

For further information contact:

Analysts and shareholders

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Media

Andrew Butcher
Bespoke Approach
Mobile: +61 400 841 088

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,000+ employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.

DR VAN ROOYEN BIOGRAPHY

Dr Jan Van Rooyen graduated as a General Practitioner in 1979 and attained a Masters' Degree in Pathology in 1987. After running a new practice in Namibia, he joined a regional pathology practice, Bouwer, in Durban, South Africa. During Bouwer's subsequent merger with two other regional practices, Dr Van Rooyen took the lead in bringing together 50 pathologists and support teams and undertaking the IT consolidation. The operations became AMPATH (the incorporated practices of Drs Du Buisson, Kramer, Swart and Bouwer). Appointed CEO in 1999, Dr Van Rooyen held the role for nearly two decades. During this time, he grew AMPATH from 70 to 160 pathologists. By 2018 AMPATH had 4000 people, 900 collection facilities and was performing ~24 million tests a year, having become the leading pathology practice in South Africa in market share (~ 40%) and in reputation for ethics and quality